Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
about
Crizotinib: from discovery to accelerated development to front-line treatmentTargeted therapies and immunotherapy in non-small-cell lung cancerTackling ALK in non-small cell lung cancer: the role of novel inhibitorsNew targeted treatments for non-small-cell lung cancer - role of nivolumabMolecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future DirectionsThe steady progress of targeted therapies, promising advances for lung cancerRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsNovel targeted agents for the treatment of lung cancer in ChinaTreating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategyTargeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughPredictive biomarkers in precision medicine and drug development against lung cancerCombating acquired resistance to tyrosine kinase inhibitors in lung cancerUpdate in Lung Cancer 2014CIViC databaseCrizotinib in ROS1-rearranged non-small-cell lung cancer.Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial.Brigatinib, an anaplastic lymphoma kinase inhibitor, abrogates activity and growth in ALK-positive neuroblastoma cells, Drosophila and mice.Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients: critical analysis of evidence and potential role in clinical practiceFocus on Alectinib and Competitor Compounds for Second-Line Therapy in ALK-Rearranged NSCLCPersonalized treatment in advanced ALK-positive non-small cell lung cancer: from bench to clinical practiceSecond- and third-generation ALK inhibitors for non-small cell lung cancerCrizotinib-Induced Abnormal Signal Processing in the RetinaSystemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Ceritinib: A primer for pharmacists.The role of local ablative therapy in oligometastatic non-small-cell lung cancer: hype or hope.Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study.Nasogastric tube-administered alectinib achieved long-term survival in a crizotinib-refractory nonsmall cell lung cancer patient with a poor performance statusA crowded, but still varied, space: brigatinib in anaplastic lymphoma kinase-rearranged non-small cell lung cancer.Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib.Alectinib induces a durable (>15 months) complete response in an ALK-positive non-small cell lung cancer patient who progressed on crizotinib with diffuse leptomeningeal carcinomatosis.In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell lineClinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases.The EML4-ALK oncogene: targeting an essential growth driver in human cancer.Alectinib for choroidal metastasis in a patient with crizotinib-resistant ALK rearranged positive non-small cell lung cancer.Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non-Small-Cell Lung Cancer or Other Tumors.
P2860
Q26738385-F57BC503-5479-4D5F-84F9-57F9C028EDB0Q26738986-ABC8C94A-88A8-444D-A463-F5970DB6C09BQ26740329-015FD7AF-9FBA-47C6-9DA9-CEB6FB9E154DQ26740988-3B94E3FA-E848-4F26-B568-9E47B621471DQ26741320-A6F8C021-34B7-416E-8071-DB6927E8CDE3Q26746895-B2BE132F-10CC-4F1B-970A-31ED60ED2410Q26747276-3777649D-1B2A-449E-8555-C56136873920Q26769879-8DD23D0D-E0A0-44B3-A0DF-BEF8A04FE024Q26786580-9F4058C7-82BF-4DD9-AE26-4AED7B0097D0Q26795555-16DE0700-0D70-4E94-801F-D06A1D6D6B6FQ26799467-BEC361D1-F7CB-4198-9439-896FE6EC5433Q26824536-5849AEFC-C6F6-4115-8C90-6E601BFCC8D3Q26824877-1E7B01EB-DA6E-4544-9830-16EDBF640FCCQ27027385-00CA929F-5B62-496B-A944-2DA0730B8470Q27612411-6F56AA47-B4AF-4AA8-8BAF-1E85EBF5B69EQ27853075-E0AE6BFF-3C10-4B2D-A883-AAFE46AA951EQ27853214-0B2BEC4E-27AC-4F11-8EC0-1EC85D83B213Q27853298-BE971453-B157-44FA-B4B9-E8880BC77106Q27853299-C3D40DD8-5F17-4CF6-A86C-9C79E2A00DB9Q27853360-708FD77A-1CB9-41B6-A994-C79A1E7D1BD8Q27853373-A65CA7B4-820E-4E34-BE54-66013F7B481BQ28066211-1CD956D9-3A29-41A1-812A-9FE33487584DQ28068643-9238EE16-C5D5-46FD-B43D-3346D438FE94Q28071903-453936EB-19FC-403B-8328-9FBDD4C02E87Q28072496-44BB6C87-CDC1-4E1D-AE8E-AF65A6DE75A3Q28547218-BE8B158B-4681-4A19-80DB-FE3C12F22DE3Q30239901-BDD80AEA-D922-4147-8A35-AE668031619AQ30244613-4A358445-3DDD-44B8-B140-8E73774CE057Q30248748-39C3C535-F916-4235-AB14-E4DF1F8E1DA5Q33591738-19C11BE1-9900-49CC-821F-D6F761A07691Q33760992-80C3E776-0B01-49C1-9AC0-7E8E9F5D9FDEQ33865475-A17C18FA-2E80-45AE-87F7-96E4CBEABA9BQ34449807-AED2E121-6683-445A-9300-B06804EE59D7Q35007620-A32F4BFA-8CB1-4A0A-8ADB-AD790DEE5CB2Q35057308-9B0D5F71-9AE0-4A69-8A3C-94B5964F6002Q35223873-475D4E70-DB05-450F-BA8A-C1D0A491C356Q35549714-599CF5C4-2B69-42F3-A73A-EB2F49BD142EQ35631006-70B7F8F2-5374-4D3A-B003-AED530C00766Q35665643-FB0DE258-580A-404D-B784-D60DC0A904C0Q35743004-4EBD0D36-F614-4879-9518-BB6B84A6DDC6
P2860
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Safety and activity of alectin ...... portion of a phase 1/2 study.
@ast
Safety and activity of alectin ...... portion of a phase 1/2 study.
@en
Safety and activity of alectin ...... portion of a phase 1/2 study.
@nl
type
label
Safety and activity of alectin ...... portion of a phase 1/2 study.
@ast
Safety and activity of alectin ...... portion of a phase 1/2 study.
@en
Safety and activity of alectin ...... portion of a phase 1/2 study.
@nl
prefLabel
Safety and activity of alectin ...... portion of a phase 1/2 study.
@ast
Safety and activity of alectin ...... portion of a phase 1/2 study.
@en
Safety and activity of alectin ...... portion of a phase 1/2 study.
@nl
P2093
P921
P3181
P1433
P1476
Safety and activity of alectin ...... portion of a phase 1/2 study.
@en
P2093
Alberto A Chiappori
Frederic Boisserie
Gregory J Riely
Howard L West
Jotaro Sato
Laura Di Laurenzio
Linta Garcia
Michele C Azada
Peter N Morcos
P304
P3181
P356
10.1016/S1470-2045(14)70362-6
P577
2014-09-01T00:00:00Z